The BRC has featured in a new guide for the bioscience industry published by the National Institute for Health Research Office for Clinical Research Infrastructure (NOCRI) and the BioIndustry Association (BIA).
The guide, ‘Navigating England’s clinical research infrastructure: How NOCRI helps simplify access to accelerate discoveries’ was launched to senior UK bioscience executives at the BIA’s CEO and Investor Forum.
The work of the BRC into developing two new disease-modifying treatments, natalizumab and dimethyfumarate, for relapsing remitting multiple sclerosis (MS) was used as a case study within the guide.
It was maintained that the BRC’s studies were crucial to show that blood-brain barrier breakdown is a key early event in new lesion formation in relapsing remitting MS. This collaboration with industry partners Biogen Idec and Elan was crucial in demonstrating that both treatments improved patient outcomes worldwide.
NOCRI was set up to help public, charity and industry research funders work in partnership with NIHR infrastructure. It ensures that NIHR-supported Centres, Units, Facilities and Networks can work together to help drive the flow of innovative research for patient benefit. For more information visit the NOCRI webpage.
